HomeAll NewsEducationTV
Equities & FundsCrypto & Digital AssetsAI & TechnologyBusiness & CorporateUS Politics & PolicyGeopolitics & Global RiskMacro, Rates & FXCommodities & EnergyEuropean Politics & MarketsAsia-PacificReal Estate & Property
Story archiveAll categories
← All Stories

Science Corp. vision chip gains EU approval

Created at 22 Jul · 6:25 PM1 source↑ Market-relevant
IN SHORT

Science Corporation's PRIMA device, designed to restore vision for those with age-related macular degeneration, has received approval from Europe's medical device regulator. The company also secured an expedited review designation from the US FDA.

✉Newsletter

PiQ Daily

Pick your topics. Get only what matters, on your cadence.

Key Numbers

300-pagenovel read by a patient
one houroutpatient procedure time

Who's Involved

Science Corporation
Developer of the PRIMA vision-restoring brain-computer interface
Max Hodak
Founder and CEO of Science Corporation, formerly of Neuralink
Europe's medical device regulator
Granted approval for the PRIMA device
US Food and Drug Administration (FDA)
Granted expedited review designation for PRIMA
Pixium
French company whose vision technology was acquired by Science Corporation
Dr. Murat Günel
Chair of Yale Medical School's Department of Neurosurgery, collaborating on bio-hybrid sensors
Science Corp. vision chip gains EU approval

↳ Why This Matters

The approval of the PRIMA device marks a significant advancement in treating vision loss from age-related macular degeneration, offering hope to millions affected by the condition and potentially paving the way for further innovations in brain-computer interfaces and medical technology.

Key facts

  • Science Corporation's PRIMA device has been approved by Europe's medical device regulator.
  • The device aims to restore vision for individuals with age-related macular degeneration.
  • PRIMA involves implanting a chip in the eye and wearing camera-equipped glasses.
  • The US FDA has granted the device a designation for expedited regulatory review.
  • Science Corporation acquired the French company Pixium, the original developer of the PRIMA technology, in 2024.

Science Corporation has secured approval from Europe's medical device regulator for its PRIMA device, which aims to restore vision lost due to age-related macular degeneration. The company also received a designation from the US Food and Drug Administration that paves the way for an expedited regulatory review, potentially allowing the device to treat two rare forms of blindness.

The PRIMA device involves a surgical procedure to implant a chip in the back of the eye, coupled with camera-equipped glasses that transmit visual information to the chip. Max Hodak, founder and CEO of Science Corporation, stated that the technology provides functional vision to individuals who have lost it, citing patient successes such as reading a novel and completing puzzles.

Hodak, previously a co-founder of Neuralink, established Science Corporation with the goal of developing novel brain-computer interfaces. The company acquired Pixium, a French firm that developed the PRIMA technology, in 2024 to advance its commercialization efforts. Science Corporation anticipates the PRIMA device will cost hundreds of thousands of dollars, and is in discussions with healthcare providers regarding reimbursement.

The company plans to launch PRIMA in Germany, where clinical trials were conducted, with the first procedures potentially occurring in September. Future developments include improving the chip and the form factor of the glasses. Science Corporation is also collaborating with Dr. Murat Günel from Yale Medical School on human trials for a directly implanted bio-hybrid brain sensor, which Hodak views as a long-term goal supported by the revenue generated from the PRIMA vision business.

Frequently asked questions

PRIMA is a brain-computer interface device designed to restore vision for individuals suffering from age-related macular degeneration and certain rare forms of blindness.

Patients undergo an outpatient procedure to implant a chip in the back of their eye, and then wear camera-equipped glasses that transmit visual data to the chip.

The approval from Europe's medical device regulator allows Science Corporation to begin selling the PRIMA device in the European market.

The US FDA has granted PRIMA a designation that is the first step toward an expedited regulatory review process.

What Happens Next

01First PRIMA procedure in Germany potentially in September.
02Discussions with healthcare providers over reimbursement for the PRIMA device.
03Continued development of PRIMA's chip and glasses.
04Preparation for human trials of a bio-hybrid brain sensor.

Get the newsletter.

Pick the topics you actually care about. We'll email when there's news worth your time, on the cadence you choose. Cancel any time from your account.

Cadence

How It Developed

Science Corporation received approval from Europe's medical device regulator for its vision-restoring chip.
The PRIMA device also received a designation from the US FDA for expedited review.
The company acquired Pixium, the French firm that developed the PRIMA technology, in 2024.
Science Corporation plans to begin offering PRIMA in Germany, with the first procedure potentially in September.
The company is also developing a bio-hybrid brain sensor with Yale Medical School's Dr. Murat Günel.

Sources

T1
Science Corporation’s vision-restoring chip wins EU approvalTechCrunch

Related Stories

J&J receives FDA authorization for robotic surgery device
22 Jul · 2:09 PM
US to spend $5 billion on AI-driven health and construction research
22 Jul · 9:07 AM
Former DOGE Staffers Launch AI Cyber Startup Cathedral With $1.4B Valuation
22 Jul · 5:53 PM
OpenAI, Anthropic Welcome Australian AI Rules Amid Global Competition
22 Jul · 3:11 PM
OpenAI plans $750B infrastructure spend, including Georgia data center
22 Jul · 4:26 PM